Korean drugmakers have secured over 50% of the market share in the six best-selling biosimilar markets, highlighting their significant impact on the global biosimilar industry. Recent developments include two companies signing an exclusive licensing partnership for a denosumab biosimilar and another two collaborating on an eculizumab biosimilar, indicating a growing interest and investment in biosimilar treatments.
Celltrion's denosumab biosimilar, CT-P41, has shown equivalent efficacy, safety, and immunogenicity compared to the originator in a phase 3 trial involving postmenopausal women with osteoporosis. This breakthrough paves the way for more accessible and cost-effective osteoporosis treatment options, potentially benefiting a wide range of patients.
In addition, Sandoz's biosimilar denosumab (Jubbonti/Wyost) has been confirmed to have analytical, pharmacokinetic, pharmacodynamic, and clinical equivalence to the reference denosumab (Prolia/Xgeva). This supports its approval and the possibility of its use across all approved indications, further expanding the treatment options available to patients.
These advancements underscore the ongoing evolution and competitiveness of the biosimilar market, with Korean drugmakers at the forefront of innovation and accessibility in healthcare.
